A year ago, Eli Lilly & Co. was poised to become the first pharmaceutical company to register a trillion-dollar market ...

Wall Street looks to stabilise after last week’s tariff-driven slump, with investors gearing up for a crucial week packed ...

The risk for major adverse cardiovascular events decreased with tirzepatide vs. liraglutide and semaglutide in patients with ...

Major pharmaceutical companies facing patent cliffs and pipeline gaps may view Viking as an attractive acquisition target if clinical data proves successful. 10 stocks we like better than Viking ...

Regeneron has received an US Food and Drug Administration (FDA) rejection for a new blood cancer therapy and expects separate regulatory delays for blockbuster ophthalmology drug Eylea HD due to ...

Novo Nordisk is misunderstood by the market, creating a rare asymmetric value opportunity. Read why I rate NVO stock a Buy ...

Drugmakers are increasingly using telehealth platforms to sell their medicines directly to patients — and President Trump is ...

Online weight-loss company Noom said on Monday it would sell copies of Novo Nordisk's Wegovy at an introductory price of $119 for up to a quarter of the branded drug's standard dose, giving patients a ...

When it was riding high, Novo Nordisk could have done M&A to reduce its dependence on obesity treatments. It didn’t.

Some of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable drugs that have grown popular in recent years for their abilities to ...

AbbVie ( ABBV) on Thursday recorded better-than-expected financials for Q2 2025 and raised its full-year earnings outlook as the company’s newer immunology drugs offset a sharp sales decline for its ...